Drug-Resistant Shigella Cases Rose in Recent Years
Extensively drug-resistant Shigella infections have increased, affecting specific high-risk populations.
Updated on Oct. 9, 2026 in COVID-19
Live Poll
Does the rise of drug-resistant infections decrease your trust in standard medical treatments?
Extensively drug-resistant (XDR) Shigella cases climbed from 0% in 2011 to 8.5% in 2023 across the United States. These resistant bacteria, which no longer respond to five standard antibiotics, have also seen rising prevalence in Canada.
Why it matters
The rise of XDR Shigella complicates treatment options for a bacterial infection that can cause severe gastrointestinal distress. Understanding this shift is important for public health surveillance and managing patient outcomes in high-risk groups.
A retrospective review identified that XDR Shigella strains increased to 8.5% of total U.S. cases by 2023, while Canadian prevalence rose to 6.6% by 2022. The analyzed data reflects a concentration of cases in men, who made up 86.2% of the study group, with 46.6% reporting HIV co-infection.
The details
Shigella is a bacteria that spreads through contaminated food, water, surfaces, and sexual contact. These XDR strains have evolved to resist all five standard antibiotics used to treat the infection, limiting clinical options for patients. Outbreaks documented in North American cities like Montreal, Calgary, and Vancouver highlight how the bacteria can circulate within communities.
Timeline
U.S. cases were analyzed from 2011 through 2023.
An outbreak occurred in Vancouver's Downtown Eastside in 2021.
A Montreal outbreak affected 56 people in September 2022.
XDR Shigella cases increased in Canada between 2018 and 2022.
A July 2024 outbreak in Calgary sickened 63 people.
Health Landscape
The emergence of XDR Shigella strains signals a significant shift in the treatment landscape for common gastrointestinal infections. This trend aligns with the WHO global list of antibiotic-resistant priority pathogens, highlighting the need for vigilance against bacteria that no longer respond to conventional care.
If you experience symptoms of Shigellosis, such as severe diarrhea, it is worth discussing your history and potential exposures with your physician. Those in high-risk groups should be particularly aware of the symptoms and consult a doctor to ensure appropriate diagnostic testing and care.
The takeaway
The rise of XDR Shigella demonstrates that bacteria can rapidly adapt to standard medical treatments, making awareness of localized outbreaks essential. Prioritize hygiene and consult a healthcare provider if you encounter symptoms, especially given the limitations of conventional antibiotic therapy for these strains.
Further reading
For broader context on managing infectious disease trends, visit the COVID-19 section.
Live Poll
Does the rise of drug-resistant infections decrease your trust in standard medical treatments?
